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Abstract-The effects of tifteen substituted phenothiazines and certain other drugs 
were studied on microsomal Na+K+-activated ATPase in rat brain to attempt to relate 
their central nervous system effects with their inhibition of enzyme activity. The mean 
control activity of the preparation was 14.4 * 0.2 pmoles Pi/mg protein/l5 min at 
37” in the presence of Na+, K+, and Mg++; and 3.3 * 0.1 in the presence of Mg++ 
alone. 
Certain substitutions on the phenothiazine nucleus were noted to increase the in- 
hibitory potency. At position 2 of the phenothiazine nucleus, a trifluoromethyl group 
was more potent than a chloro group which was in turn more potent than hydrogen. 
At position 10, a piperazine side chain was more inhibitory than an aliphatic amine 
substitution. The sulfoxide derivatives of promazine, chlorpromazine, and triflu- 
promazine did not inhibit Na+K+-ATPase activity at concentrations as high as 
5 x 1O-4 M. 
Compounds which failed to influence Na+K+-ATPase activity at concentrations 
used in the phenothiazine studies were pentylenetetrazol, d-amphetamine, strychnine, 
y-aminobutyric acid, and pentobarbital. 
The evidence in this report suggests that, for substituted phenothiazines, there may 
be a correlation between inhibition of brain Na+K+-ATPase activity in vitro and 
certain central nervous system effects in viz~o. 
A Na+K+-activated Mg++-dependent adenosine triphosphatase was first reported in 
crab nerve by Skou in 1957.1 Subsequent work, summarized in recent reviews, has 
established the nearly ubiquitous occurrence of a similar Na+K+-activated ATPase 
in most of the biological tissues that have been studied and has also established a 
striking correlation between the properties of this enzymatic system and features of 
active transport of monovalent cations.2T 3 
Inhibition of Na+K+-activated ATPase activity in rat brain by phenothiazines such 
as promethazine and chlorpromazine has been reported previously.49 5 
The purpose of this report is to present recent findings which suggest a correlation 
between the potency of phenothiazines inhibiting brain Na+K+-ATPase in vitro and 
the tranquilizing potency of the same agents in vivo. 
EXPERIMENTAL 
Male albino rats (250-350 g) were sacrificed by decapitation. The ‘entire cerebrum, 
cerebellum, and brain stem were removed from each of four animals and pooled 
* A preliminary account of this work was presented before the American Society for Pharmacology 
and Experimental Therapeutics on August 17, 1965, in Philadelphia, Pa. (Pharmacologist 7, 141, 1965). 
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immediately in ice-cold 0.25 M sucrose. All subsequent operations were performed 
at temperatures of O-4”. A 1 :lO tissue homogenate in O-25 M sucrose was prepared 
in a hand-driven Dounce ball-type homogenizer. Unbroken cells, nuclei, and mito- 
chondria were removed by centrifugation at 1000 g for 20 min and 12,000 g for 30 
min in a Serval RC2 centrifuge. The 12,000-g/30_minutes supernatant was placed 
in a Spinco model L ultracentrifuge at 35,000 g for 30 min. After removal of the 
35,000-g supernatant by decantation, the heavy microsomal pellet was gently re- 
suspended by hand homogenization in O-25 M sucrose and subjected to a second 
35,000-g centrifugation for 30 min. The heavy microsomal pellet was then resuspended 
in O-25 M sucrose and diIuted with an equal volume of 0.2% deoxycholic acid after 
neutralization to pH 7.5 with 0 1 M Tris. The preparation was stored at 0” for 2 to 3 
days prior to use. Theuse of deoxycholic acid increased total activity (Na,K,Mg) slightly 
while increasing the NaKMg/Mg activity ratio with a twofold increase in the NaK 
component. This is in confirmation of the findings of others who have used the brain 
microsomal preparation.6-s 
The Na+-K+-ATPase activity of the heavy microsomal suspension was measured 
under the following conditions: Tris-ATP {Sigma Chemical Co.) 3 mM; MgCla 3 mM; 
N&I 100 mM; KC1 15 mM; choline Cl I15 mM (as an osmotic substitute in tubes 
where Na+ and K-t were omitted); Tris-HCI 30 mM at pH 7.5; and O-2 ml of the 
heavy microsomai suspension in a totai incubation volume of 2.0 ml. Incubation was 
at 37” for 15 min and was terminated by the addition of I,0 ml of 1.5 N perchloric 
acid. After removal of the precipitated protein by centrifugation, an aliquot of the 
incubation medium was assayed for inorganic phosphate by the Fiske and SubbaRow 
method.9 The protein content of the preparation was determined by a modified 
biuret technique.10 
Phenothiazines tested as inhibitors of brain Na+K+-ATPase activity included: 
promazine HCI, promethazine HCl, and propiomazine HCl (Wyeth Laboratories); 
chlorpromazine HCI, prochlorperazine edisyiate, and trifluoperazine diHC1 (Smith, 
Kline & French Laboratories); thioridazine HCI and thiethylperazine maleate 
(Sandoz Pharmaceuticals); mepazine HCI (Warner-Chilcott Laboratories); per- 
phenzine (Schering Corp.); triflupromazine (Squibb & Sons); and fluphenazine 
diHCl (White Laboratories). The phenothiazine analog imipramine (Geigy Pharma- 
ceuticals) was employed also. The sulfoxide derivatives of promazine, chlorpromazine, 
and trifluoperazine were kindly supplied by Dr. Harry Green, Smith, Kline & French 
Laboratories. 
RESULTS 
Control ATPase activity in the presence of Na-+, K+, and Mg++ was 14.4 -J= 0.2 
pmoles PJmg protein/l5 min at 37” as compared with 3.3 & 0.1 obtained in the 
presence of Mg++ alone; i.e. a fourfold increase above Mg++-dependent ATPase 
activity as a result of NafK-activation. In all experiments, drugs to be tested were 
included in the Mg as well as in the NaKMg tubes. All data are expressed as per cent 
inhibition of Na+K+-ATPase activity of the drug-treated enzyme compared with 
control-Na+K+ATPase activity being defined as the difference between the total 
activity (NaKMg) and Mg-~~-dependent ATPase activity. 
Phenothi~n~ and Na+K+-ATPase 
I I 
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Phenothiazines and Na+K+-ATPase 101 
Values for inhibition of Na+K+-ATPase activity by various substituted pheno- 
thiazines are presented in Table 1. Each value listed is the mean of either three or 
five independent experiments as indicated. Each individual experiment within such 
a series was performed on a different day, in duplicate, with microsomal suspensions 
from different animals and independently prepared drug solutions. The per cent 
STATISTICAL COMPARISONSFROMTABLE 1 DATA 
P value 
1 x 10-4M 5 x lo-5M 
Triflupromazine vs. chlorpromazine 
Chlorpromazine vs. promazine 
Trifluoperazine vs. prochlorperazine 
Fluphenazine vs. perphenazine 
Prochlorperazine vs. chlorpromazine 
Trifluoperazine vs. triflupromazine 
Fluphenazine vs. triflupromazine 
Promazine vs. promazine sulfoxidet 
Chlorpromazine vs. chlorpromazine sulfoxide 









<O.OOl < 0.025 
<OWl < 0.005 
* NS = not significant at 0.05 level. 
t At a higher concentration of the drugs (5 x lo-*M), where the inhibition values for promazine 
and promazine sulfoxide were 77.0 & 1.8 (N = 5) and -1.0 & 4.2 (N = 3), respectively, the differ- 
ence was significant, P < 0031. 
inhibition values in a single experiment were calculated on the basis of the control 
activity of that day. 
The substituted phenothiazines studied differed from one another in the RI and Rz 
substituents at positions 10 and 2 of the phenothiazine nucleus (Fig. 1). Two patterns 
FIG. 1. Substituted groups on the phenothiazine nucleus. 
of structure-activity relationships were noted between substituted groups on the 
phenothiazine nucleus and inhibition of Na+K+-ATPase. 
Certain changes in the Rs group resulted in marked differences in inhibitory potency. 
A trifluoromethyl substitution inhibited more than a corresponding chloro group 
which, in turn, was more potent than hydrogen substituted in the same position. 
For example, 1 x 10d4 M triflupromazine (which contains a trifluoromethyl group 
at Rs) inhibited enzyme activity by 65 per cent as compared to only 38 per cent 
inhibition obtained with the chloro analog, chlorpromazine, at the same concentration. 
Chlorpromazine at 1 x 1O-4 M was more inhibitory than promazine which has an 
unsubstituted hydrogen at Ra and which inhibited only 6 per cent at this concentration. 
The inhibition by promazine at 10 -4 M did not differ significantly from control 
activity at the 5 per cent confidence level. However, a higher concentration of this 
compound (5 x 10-d M) reduced control activity by 77 & l-8 % (N = 5). The values 
for other agents at this concentration are not presented in Table 1 since all compounds 
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gave complete inhibition of enzyme activity. Triflupromazine, chlorpromazine, and 
promazine differ in structure only at Re, the Ri group being dimethylaminopropyl, 
common to all three compounds. 
Another example of the increased potency of a trifluoromethyl substitution relative 
to a chloro group was noted in the 50 per cent inhibition by trifluoperazine as com- 
pared with an inhibition of only 33 per cent by prochlorperazine when 5 x 10-5 M of 
each agent was compared with control activity. These two compounds have identical 
piperazine side-chain moieties and differ structurally only at Ra. A third illustration 
of the greater inhibitory potency of a trifluoromethyl group was seen with fluphenazine 
and perphenazine. Fluphenazine with a trifluoromethyl group at RB inhibited 80 per 
cent at 1 x 10-d M, whereas the chloro analog, perphenazine, inhibited only 55 per 
cent at the same concentration. 
In addition to the above structural changes in the Rs group, the nature of the 
substituent in Ri also appeared to be a factor in determining inhibitory potency. 
In general, a side chain containing a piperazine moiety led to greater reduction in 
control activity than did an aliphatic amine side chain. In comparing prochlorperazine 
and chlorpromazine, differing only in the Ri moiety, the former, which has a pipera- 
zine side chain, inhibited 88 per cent at 1 x 1O-4 M, whereas the latter, an aliphatic 
amine, produced a fall of only 38 per cent in enzyme activity at the same concentration. 
Also, the piperazine compounds trifluoperazine and fluphenazine were more potent at 
1 x IO-4 M (inhibiting 98 per cent and 80 per cent respectively) than the aliphatic 
amine triflupromazine which reduced enzyme activity by only 65 per cent. These three 
compounds differ only at Ri, since Ra is trifluoromethyl in each. In addition, although 
no direct comparison was possible since the Ra groups are not constant, the aliphatic 
amines promethazine and propiomazine produced only moderate inhibition when 
compared to the more potent piperazine compounds. 
Promazine sulfoxide, chlorpromazine sulfoxide, and trifluoperazine sulfoxide 
did not significantly inhibit Na+K+-ATPase activity at 1 x lOA M, whereas the 
parent compounds, promazine, chlorpromazine, and trifluoperazine, produced 
6, 38 and 98 per cent inhibition respectively at the same concentration. 
Imipramine, a nonphenothiazine analog of promazine, produced weak inhibition 
quite similar in magnitude to that seen with promazine. While imipramine did not 
significantly reduce Na+K+-ATPase activity at 1 x 10M4 M, a higher concentration 
of this compound (5 x 1O-4 M) produced 59 _Ir 6.4 per cent inhibition (mean * S.E., 
N = 3), a value similar to that obtained with promazine at the same concentration. 
With regard to piperidyl structures, mepazine produced moderate inhibition, whereas 
marked inhibition was obtained with thioridazine. 
Compounds that failed to influence Na+K+-ATPase activity at the concentrations 
used in the phenothiazine studies included pentylenetetrazol, d-amphetamine, strych- 
nine, y-aminobutyric acid, and pentobarbital. These compounds were ineffective in 
concentrations as high as 5 x 1O-4 M. 
DISCUSSION 
Substituted phenothiazines exert numerous effects upon the central nervous 
system. Commonly measured parameters include antiemetic action, extrapyramidal 
signs, depression of conditioned-avoidance responses, and antipsychotic effects 
clinically. In attempting to correlate enzyme inhibition in vitro with central nervous 
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system actions in vivo, any of these central nervous system actions might conceivably 
be selected as a response correlate in vivo. 
It is interesting to note that the structure-activity relationships between substituted 
phenothiazines and inhibition in vitro of Na+K+-ATPase reported in this paper are in 
accord with several major structure-activity relationships generally considered in 
regard to certain effects of substituted phenothiazines in vivo on the central nervous sys- 
tem. The only compound that appears to fall out of line is thioridazine which, on clini- 
cal impression and other studies in vivo, has a potency comparable to or possibly 
even weaker than chlorpromazine, yet in the present study appears to be as potent an 
inhibitor as prochlorperazine. 
Increased potency for depression of conditioned-avoidance responses in animals 
and increased antipsychotic action clinically in humans has resulted from substitutions 
in the RZ group where a trifluoromethyl moiety is more potent than a chlorine sub- 
stitution which in turn is more potent than hydrogen; e.g. triflupromazine > chlor- 
promazine > promazine. Another example is the greater potency of trifluoperazine 
relative to that of prochlorperazine.11 
These same central nervous system actions have been shown to be greater for 
piperazine structures than for aliphatic amines in the RI group; e.g. prochlor- 
perazine > chlorpromazine. Also, both trifluoperazine and fluphenazine exert stronger 
actions than triflupromazine. The sulfoxide metabolites which fail to depress Na+K+- 
ATPase in the present study are known to possess little central nervous system 
activity.121 l3 
In recent years many studies have suggested correlations between various bio- 
chemical and physicochemical effects of the substituted phenothiazines and their 
clinical effectiveness as tranquilizers. Much of this work has been recently reviewed 
by Guth and Spirtes,lh who offer a unifying hypothesis suggesting that changes in 
membrane permeability induced by phenothiazines may be the basis for many of the 
reported biochemical actions of phenothiazines. They postulate that the phenothia- 
zines act as “membrane stabilizers”. In view of the present report of phenothiazine 
inhibition of brain Na+K+-ATPase, an enzyme believed to be intimately involved in 
active transport of monovalent cations across membrane barriers, it is tempting to 
speculate that inhibition of such an enzyme might explain the changes in ion and 
water transfer processes seen in studies of changes in membrane permeability. Thus, 
these data are not inconsistent with the hypothesis that the phenothiazines act by 
membrane stabilization and suggest in addition an enzyme site where such an effect 
may occur. 
Two other classes of pharmacological agents are also capable of inhibiting Na+K+- 
ATPase activity-the cardiac glycosideslsa 16 and the organic mercurial diuretics.l’* 1s 
RepkelQ has correlated the inhibition of Na+K+-ATPase with the chemical structure 
and potency of the various cardiac glycosides, and Jones et al.20 have attempted to 
relate diuretic potency and ATPase inhibition of certain diuretics. It is interesting to 
note that the phenothiazine tranquilizers can produce ventricular fibrillation in man 
when large doses of the drug are administered,21 an action characteristic of cardiac 
glycoside toxicity. 
The question of whether the drug concentrations used in the present study have any 
relevance to those one might expect in vivo, is difficult to answer because of the nature 
of the compounds. Generally the concentrations used here are of the same order of 
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magnitude as those’used in other experiments in vitro. l4 Several studies have demon- 
strated that the phenothiazines are avidly taken up by tissues, particularly brain. 
For example, Saltzman and Brodie22 found chlorpromazine to be concentrated some 
go-fold in brain after administration to dogs. De Jaramillo and Guth23 have deter- 
mined that the levels of phenothiazines in the hypothalamus of the dog might be as 
high as 5 x 10-4 M, with possibly still higher concentrations in subcellular com- 
ponents.241 25 On the other hand, Gillette 26 has postulated that because the per- 
centage of binding of the phenothiazines is so high and because the binding is rever- 
sible, the amount of free or unbound drug must be extremely small (about 5 x 1O-7 
M). He suggests that concentrations in this range are those that should be considered 
to interact with the receptor to produce the pharmacological effect. Since no measure- 
ments of free drug were made in the present study, it is impossible to assess this 
aspect of the work. However, none of the above considerations negates the findings of a 
positive correlation between potency in vivo and ability of these agents to inhibit 
brain Na+K+-ATPase activity. 
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